TY - JOUR
T1 - Mask-induced Koebner phenomenon and its clinical phenotypes
T2 - A multicenter, real-life study focusing on 873 dermatological consultations during COVID-19 pandemics
AU - Young Dermatologists Italian Network
AU - Damiani, Giovanni
AU - Gironi, Laura Cristina
AU - Kridin, Khalaf
AU - Pacifico, Alessia
AU - Buja, Alessandra
AU - Bragazzi, Nicola Luigi
AU - Spalkowska, Magdalena
AU - Pigatto, Paolo Daniele Maria
AU - Santus, Pierachille
AU - Savoia, Paola
N1 - Publisher Copyright:
© 2021 Wiley Periodicals LLC.
PY - 2021/3/1
Y1 - 2021/3/1
N2 - During COVID-19 pandemic, wearing masks for prevention became mandatory but evidence suggest that is also detrimental for skin. Although facial dermatoses due to masks increase in both healthcare workers and general population, a pathogenetic hypothesis remains still elusive. We aimed to evaluate the prevalence of dermatological consultations due to Koebner triggered dermatoses In this prospective, multicenter, real life study carried out in Italy from March 11th to December 11th 2020 during COVID-19 pandemics, dermatological consultations (in-person and telemedicine) to study the prevalence of Koebner (KB) phenomenon due to masks were evaluated. Boyd and Nelder classification was adopted for Koebner phenomenon and Bizzozero's for KB intensity. A total of 229/873 (26.2%) dermatological consultations were KB triggered dermatoses and lesions were located in mask-covered ear area (76 [33.2%]), malar area (73 [31.8%]), perioral area (53 [23.1%]), and nose (27 [11.8%]). The first KB category grouped 142 patients (psoriasis, vitiligo, maskne, and mask rosacea), the second one 24 (warts, molluscum contagiosum, and impetigo), the third one 46 (atopic dermatitis), and the fourth one 17 (eczema). Among previously KB negative psoriatic patients that became KB positive, 9/13 (69.2%) had discontinued or modified the prescribed antipsoriatic treatment. Mask-related Koebner phenomenon is an important clinical sign to orient clinician's therapeutic protocols during COVID-19 pandemic, especially in patients with psoriasis.
AB - During COVID-19 pandemic, wearing masks for prevention became mandatory but evidence suggest that is also detrimental for skin. Although facial dermatoses due to masks increase in both healthcare workers and general population, a pathogenetic hypothesis remains still elusive. We aimed to evaluate the prevalence of dermatological consultations due to Koebner triggered dermatoses In this prospective, multicenter, real life study carried out in Italy from March 11th to December 11th 2020 during COVID-19 pandemics, dermatological consultations (in-person and telemedicine) to study the prevalence of Koebner (KB) phenomenon due to masks were evaluated. Boyd and Nelder classification was adopted for Koebner phenomenon and Bizzozero's for KB intensity. A total of 229/873 (26.2%) dermatological consultations were KB triggered dermatoses and lesions were located in mask-covered ear area (76 [33.2%]), malar area (73 [31.8%]), perioral area (53 [23.1%]), and nose (27 [11.8%]). The first KB category grouped 142 patients (psoriasis, vitiligo, maskne, and mask rosacea), the second one 24 (warts, molluscum contagiosum, and impetigo), the third one 46 (atopic dermatitis), and the fourth one 17 (eczema). Among previously KB negative psoriatic patients that became KB positive, 9/13 (69.2%) had discontinued or modified the prescribed antipsoriatic treatment. Mask-related Koebner phenomenon is an important clinical sign to orient clinician's therapeutic protocols during COVID-19 pandemic, especially in patients with psoriasis.
KW - COVID-19
KW - Koebner clinical phenotypes
KW - Koebner mask induced
KW - facial dermatoses
KW - personal protective equipment
KW - psoriasis
KW - surgical masks
KW - telemedicine
UR - http://www.scopus.com/inward/record.url?scp=85101063975&partnerID=8YFLogxK
U2 - 10.1111/dth.14823
DO - 10.1111/dth.14823
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 33527560
AN - SCOPUS:85101063975
SN - 1396-0296
VL - 34
JO - Dermatologic Therapy
JF - Dermatologic Therapy
IS - 2
M1 - e14823
ER -